Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allo-JaCE03 is a dried allogeneic cultured epidermis developed by Japan Tissue Engineering Co., Ltd. (J-TEC) for the treatment of deep dermal burns. It is an off-the-shelf regenerative medicine product composed of human keratinocytes cultured from donor skin and subsequently processed into a dried sheet. Unlike autologous cultured epidermis, which requires a biopsy from the patient and several weeks of cultivation, Allo-JaCE03 can be stored and applied immediately to burn wounds. The product acts as a biological scaffold that promotes wound healing and epithelialization by releasing essential cytokines and growth factors that stimulate the migration and proliferation of the patient's own keratinocytes. Clinical trials in Japan, including a pivotal confirmatory study, have demonstrated that Allo-JaCE03 significantly improves epithelialization rates in patients with extensive deep dermal burns with a favorable safety profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Allo-JaCE03.